当前位置: 首页 >> 检索结果
201. Blood Pressure and Oxygen Targets on Kidney Injury After Cardiac Arrest.
作者: Sebastian Buhl Rasmussen.;Karoline Korsholm Jeppesen.;Jesper Kjaergaard.;Christian Hassager.;Henrik Schmidt.;Simon Mølstrøm.;Rasmus Paulin Beske.;Johannes Grand.;Hanne Berg Ravn.;Matilde Winther-Jensen.;Martin Abild Stengaard Meyer.;Jacob Eifer Møller.
来源: Circulation. 2023年148卷23期1860-1869页
Acute kidney injury (AKI) represents a common and serious complication to out-of-hospital cardiac arrest. The importance of post-resuscitation care targets for blood pressure and oxygenation for the development of AKI is unknown.
202. Computed Tomography Cardiac Angiography Before Invasive Coronary Angiography in Patients With Previous Bypass Surgery: The BYPASS-CTCA Trial.
作者: Daniel A Jones.;Anne-Marie Beirne.;Matthew Kelham.;Krishnaraj S Rathod.;Mervyn Andiapen.;Lucinda Wynne.;Thomas Godec.;Nasim Forooghi.;Rohini Ramaseshan.;James C Moon.;Ceri Davies.;Christos V Bourantas.;Andreas Baumbach.;Charlotte Manisty.;Andrew Wragg.;Amrita Ahluwalia.;Francesca Pugliese.;Anthony Mathur.; .
来源: Circulation. 2023年148卷18期1371-1380页
Patients with previous coronary artery bypass grafting often require invasive coronary angiography (ICA). However, for these patients, the procedure is technically more challenging and has a higher risk of complications. Observational studies suggest that computed tomography cardiac angiography (CTCA) may facilitate ICA in this group, but this has not been tested in a randomized controlled trial.
203. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
作者: Peter A Henriksen.;Peter Hall.;Iain R MacPherson.;Shruti S Joshi.;Trisha Singh.;Morag Maclean.;Steff Lewis.;Aryelly Rodriguez.;Alex Fletcher.;Russell J Everett.;Harriet Stavert.;Angus Broom.;Lois Eddie.;Lorraine Primrose.;Heather McVicars.;Pam McKay.;Annabel Borley.;Clare Rowntree.;Simon Lord.;Graham Collins.;John Radford.;Amy Guppy.;Michelle C Williams.;Alan Japp.;John R Payne.;David E Newby.;Nicholas L Mills.;Olga Oikonomidou.;Ninian N Lang.
来源: Circulation. 2023年148卷21期1680-1690页
Anthracycline-induced cardiotoxicity has a variable incidence, and the development of left ventricular dysfunction is preceded by elevations in cardiac troponin concentrations. Beta-adrenergic receptor blocker and renin-angiotensin system inhibitor therapies have been associated with modest cardioprotective effects in unselected patients receiving anthracycline chemotherapy.
204. Complete Revascularization Versus Culprit-Lesion-Only PCI in STEMI Patients With Diabetes and Multivessel Coronary Artery Disease: Results From the COMPLETE Trial.
作者: Zardasht Oqab.;Vijay Kunadian.;David A Wood.;Robert F Storey.;Sunil V Rao.;Roxana Mehran.;Natalia Pinilla-Echeverri.;Thenmozhi Mani.;Robert H Boone.;Saleem Kassam.;Matthias Bossard.;Samer Mansour.;Warren Ball.;Matthew Sibbald.;Nicholas Valettas.;Raul Moreno.;Philippe Gabriel Steg.;John A Cairns.;Shamir R Mehta.
来源: Circ Cardiovasc Interv. 2023年16卷9期e012867页
In the COMPLETE trial (Complete Versus Culprit-Only Revascularization to Treat Multivessel Disease After Early PCI for STEMI), a strategy of complete revascularization reduced the risk of major cardiovascular events compared with culprit-lesion-only percutaneous coronary intervention in patients presenting with ST-segment-elevation myocardial infarction (STEMI) and multivessel coronary artery disease. Patients with diabetes have a worse prognosis following STEMI. We evaluated the consistency of the effects of complete revascularization in patients with and without diabetes.
205. Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial.
作者: Derek S Chew.;Yanhong Li.;Robert Bigelow.;Patricia A Cowper.;Kevin J Anstrom.;Melanie R Daniels.;Linda Davidson-Ray.;Adrian F Hernandez.;Christopher M O'Connor.;Paul W Armstrong.;Daniel B Mark.; .
来源: Circulation. 2023年148卷14期1087-1098页
The VICTORIA trial (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) demonstrated that, in patients with high-risk heart failure, vericiguat reduced the primary composite outcome of cardiovascular death or heart failure hospitalization relative to placebo. The hazard ratio for all-cause mortality was 0.95 (95% CI, 0.84-1.07). In a prespecified analysis, treatment effects varied substantially as a function of baseline NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, with survival benefit for vericiguat in the lower NT-proBNP quartiles (hazard ratio, 0.82 [95% CI, 0.69-0.97]) and no benefit in the highest NT-proBNP quartile (hazard ratio, 1.14 [95% CI, 0.95-1.38]). An economic analysis was a major secondary objective of the VICTORIA research program.
206. Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial.
作者: Yugo Yamashita.;Takeshi Morimoto.;Nao Muraoka.;Takuya Oyakawa.;Michihisa Umetsu.;Daijirou Akamatsu.;Yuji Nishimoto.;Yukihito Sato.;Takuma Takada.;Kentaro Jujo.;Yuichiro Minami.;Yoshito Ogihara.;Kaoru Dohi.;Masashi Fujita.;Tatsuya Nishikawa.;Nobutaka Ikeda.;Go Hashimoto.;Kazunori Otsui.;Kenta Mori.;Daisuke Sueta.;Yukari Tsubata.;Masaaki Shoji.;Ayumi Shikama.;Yutaka Hosoi.;Yasuhiro Tanabe.;Ryuki Chatani.;Kengo Tsukahara.;Naohiko Nakanishi.;Kitae Kim.;Satoshi Ikeda.;Makoto Mo.;Yusuke Yoshikawa.;Takeshi Kimura.; .
来源: Circulation. 2023年148卷21期1665-1676页
The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events; however, it could also increase the risk of bleeding.
207. Cardiac Magnetic Resonance Imaging Versus Computed Tomography to Guide Transcatheter Aortic Valve Replacement: A Randomized, Open-Label, Noninferiority Trial.
作者: Martin Reindl.;Ivan Lechner.;Magdalena Holzknecht.;Christina Tiller.;Priscilla Fink.;Fritz Oberhollenzer.;Sebastian von der Emde.;Mathias Pamminger.;Felix Troger.;Christian Kremser.;Elisabeth Laßnig.;Kathrin Danninger.;Ronald K Binder.;Hanno Ulmer.;Christoph Brenner.;Gert Klug.;Axel Bauer.;Bernhard Metzler.;Agnes Mayr.;Sebastian J Reinstadler.
来源: Circulation. 2023年148卷16期1220-1230页
Computed tomography (CT) is recommended for guiding transcatheter aortic valve replacement (TAVR). However, a sizable proportion of TAVR candidates have chronic kidney disease, in whom the use of iodinated contrast media is a limitation. Cardiac magnetic resonance imaging (CMR) is a promising alternative, but randomized data comparing the effectiveness of CMR-guided versus CT-guided TAVR are lacking.
208. Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.
作者: Linda P T Joosten.;Sander van Doorn.;Peter M van de Ven.;Bart T G Köhlen.;Melchior C Nierman.;Huiberdina L Koek.;Martin E W Hemels.;Menno V Huisman.;Marieke Kruip.;Laura M Faber.;Nynke M Wiersma.;Wim F Buding.;Rob Fijnheer.;Henk J Adriaansen.;Kit C Roes.;Arno W Hoes.;Frans H Rutten.;Geert-Jan Geersing.
来源: Circulation. 2024年149卷4期279-289页
There is ambiguity whether frail patients with atrial fibrillation managed with vitamin K antagonists (VKAs) should be switched to a non-vitamin K oral anticoagulant (NOAC).
209. Optical Coherence Tomography-Guided or Intravascular Ultrasound-Guided Percutaneous Coronary Intervention: The OCTIVUS Randomized Clinical Trial.
作者: Do-Yoon Kang.;Jung-Min Ahn.;Sung-Cheol Yun.;Seung-Ho Hur.;Yun-Kyeong Cho.;Cheol Hyun Lee.;Soon Jun Hong.;Subin Lim.;Sang-Wook Kim.;Hoyoun Won.;Jun-Hyok Oh.;Jeong Cheon Choe.;Young Joon Hong.;Yong-Hoon Yoon.;Hoyun Kim.;Yeonwoo Choi.;Jinho Lee.;Young Won Yoon.;Soo-Joong Kim.;Jang-Ho Bae.;Duk-Woo Park.;Seung-Jung Park.; .
来源: Circulation. 2023年148卷16期1195-1206页
Intravascular imaging-guided percutaneous coronary intervention (PCI) with intravascular ultrasound (IVUS) or optical coherence tomography (OCT) showed superior clinical outcomes compared with angiography-guided PCI. However, the comparative effectiveness of OCT-guided and IVUS-guided PCI regarding clinical outcomes is unknown.
210. Biodegradable-Polymer or Durable-Polymer Stents in Patients at High Bleeding Risk: A Randomized, Open-Label Clinical Trial.
作者: Marco Valgimigli.;Adrian Wlodarczak.;Ralph Tölg.;Béla Merkely.;Henning Kelbæk.;Jacek Legutko.;Stefano Galli.;Matthieu Godin.;Gabor G Toth.;Thibault Lhermusier.;Benjamin Honton.;Peter Laurenz Dietrich.;Francis Stammen.;Bert Ferdinande.;Johanne Silvain.;Davide Capodanno.;Guillaume Cayla.; .
来源: Circulation. 2023年148卷13期989-999页
Limited information is available on the comparative efficacy and safety of different stent platforms in patients at high bleeding risk undergoing an abbreviated dual antiplatelet therapy duration after percutaneous coronary intervention (PCI). The aim of this study was to compare the safety and effectiveness of the biodegradable-polymer sirolimus-eluting stent with the durable-polymer zotarolimus-eluting stent in patients at high bleeding risk receiving 1 month of dual antiplatelet therapy after PCI.
211. Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
作者: Milton Packer.;Javed Butler.;Cordula Zeller.;Stuart J Pocock.;Martina Brueckmann.;João Pedro Ferreira.;Gerasimos Filippatos.;Muhammad Shariq Usman.;Faiez Zannad.;Stefan D Anker.
来源: Circulation. 2023年148卷13期1011-1022页
It is not known whether the benefits of sodium-glucose cotransporter 2 inhibitors in heart failure persist after years of therapy.
212. Fractional Flow Reserve-Guided PCI or Coronary Bypass Surgery for 3-Vessel Coronary Artery Disease: 3-Year Follow-Up of the FAME 3 Trial.
作者: Frederik M Zimmermann.;Victoria Y Ding.;Nico H J Pijls.;Zsolt Piroth.;Albert H M van Straten.;Laszlo Szekely.;Giedrius Davidavicius.;Gintaras Kalinauskas.;Samer Mansour.;Rajesh Kharbanda.;Nikolaos Östlund-Papadogeorgos.;Adel Aminian.;Keith G Oldroyd.;Nawwar Al-Attar.;Nikola Jagic.;Jan-Henk E Dambrink.;Petr Kala.;Oskar Angeras.;Philip MacCarthy.;Olaf Wendler.;Filip Casselman.;Nils Witt.;Kreton Mavromatis.;Steven E S Miner.;Jaydeep Sarma.;Thomas Engstrøm.;Evald H Christiansen.;Pim A L Tonino.;Michael J Reardon.;Hisao Otsuki.;Yuhei Kobayashi.;Mark A Hlatky.;Kenneth W Mahaffey.;Manisha Desai.;Y Joseph Woo.;Alan C Yeung.;Bernard De Bruyne.;William F Fearon.; .
来源: Circulation. 2023年148卷12期950-958页
Previous studies comparing percutaneous coronary intervention (PCI) with coronary artery bypass grafting (CABG) in patients with multivessel coronary disease not involving the left main have shown significantly lower rates of death, myocardial infarction (MI), or stroke after CABG. These studies did not routinely use current-generation drug-eluting stents or fractional flow reserve (FFR) to guide PCI.
213. Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial.
作者: Divaka Perera.;Holly P Morgan.;Matthew Ryan.;Matthew Dodd.;Tim Clayton.;Peter D O'Kane.;John P Greenwood.;Simon J Walsh.;Roshan Weerackody.;Adam McDiarmid.;George Amin-Youssef.;Julian Strange.;Bhavik Modi.;Timothy Lockie.;Kai Hogrefe.;Fozia Z Ahmed.;Miles Behan.;Nicholas Jenkins.;Eltigani Abdelaal.;Michelle Anderson.;Stuart Watkins.;Richard Evans.;Christopher A Rinaldi.;Mark C Petrie.; .
来源: Circulation. 2023年148卷11期862-871页
Ventricular arrhythmia is an important cause of mortality in patients with ischemic left ventricular dysfunction. Revascularization with coronary artery bypass graft or percutaneous coronary intervention is often recommended for these patients before implantation of a cardiac defibrillator because it is assumed that this may reduce the incidence of fatal and potentially fatal ventricular arrhythmias, although this premise has not been evaluated in a randomized trial to date.
214. Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
作者: Barry A Borlaug.;Yogesh N V Reddy.;Amanda Braun.;Hidemi Sorimachi.;Massar Omar.;Dejana Popovic.;Alessio Alogna.;Michael D Jensen.;Rickey Carter.
来源: Circulation. 2023年148卷10期834-844页
Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but the hemodynamic mechanisms underlying these benefits remain unclear. This study sought to determine whether treatment with dapagliflozin affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in patients with HFpEF.
215. EXACT Trial: Results of the Phase 1 Dose-Escalation Study.
作者: Thomas J Povsic.;Timothy D Henry.;Jay H Traverse.;R David Anderson.;Geoffrey A Answini.;Benjamin C Sun.;George J Arnaoutakis.;Konstantinos D Boudoulas.;Adam R Williams.;Howard C Dittrich.;Elizabeth A Tarka.;David A Latter.;E Magnus Ohman.;Mark W Peterson.;Dawn Byrnes.;Carl J Pepine.;Marcelo F DiCarli.;Ronald G Crystal.;Todd K Rosengart.;Nahush A Mokadam.
来源: Circ Cardiovasc Interv. 2023年16卷8期e012997页
New therapies are needed for patients with refractory angina. Encoberminogene rezmadenovec (XC001), a novel adenoviral-5 vector coding for all 3 major isoforms of VEGF (vascular endothelial growth factor), demonstrated enhanced local angiogenesis in preclinical models; however, the maximal tolerated dose and safety of direct epicardial administration remain unknown.
216. DASH-HF Study: A Pragmatic Quality Improvement Randomized Implementation Trial for Patients With Heart Failure With Reduced Ejection Fraction.
作者: Aradhana Verma.;Gregg C Fonarow.;Jeffrey J Hsu.;Cynthia A Jackevicius.;Freny Vaghaiwalla Mody.;Amanda Nguyen.;Omid Amidi.;Sarah Goldberg.;Reeta Vetrivel.;Deepti Upparapalli.;Kleanthis Theodoropoulos.;Stephanie Gregorio.;Donald S Chang.;Kristina Bostrom.;Andrew D Althouse.;Boback Ziaeian.
来源: Circ Heart Fail. 2023年16卷9期e010278页
Heart failure is a prevailing diagnosis of hospitalization and readmission within 6 months, and nearly a quarter of these patients die within a year. Guideline-directed medication therapies reduce risk of mortality by 73% over 2 years; however, the implementation of these therapies to their target dose in clinical practice continues to be challenging. In 2020, the Veterans Affairs (VA) Health Care System developed a HF dashboard to monitor and improve outpatient HF management. The DASH-HF (Dashboard Activated Services and Telehealth for Heart Failure) study is a randomized, pragmatic clinical trial to evaluate proactive dashboard-directed telehealth clinics to improve the use and dosing of guideline-directed medication therapy for patients with heart failure with reduced ejection fraction not on optimal guideline-directed medication therapy within the VA.
217. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction: A Randomized, Open-Label Trial.
作者: Frans Van de Werf.;Arsen D Ristić.;Oleg V Averkov.;Alexandra Arias-Mendoza.;Yves Lambert.;José F Kerr Saraiva.;Pablo Sepulveda.;Fernando Rosell-Ortiz.;John K French.;Ljilja B Musić.;Katleen Vandenberghe.;Kris Bogaerts.;Cynthia M Westerhout.;Alain Pagès.;Thierry Danays.;Kevin R Bainey.;Peter Sinnaeve.;Patrick Goldstein.;Robert C Welsh.;Paul W Armstrong.; .
来源: Circulation. 2023年148卷9期753-764页
ST-segment-elevation myocardial infarction (STEMI) guidelines recommend pharmaco-invasive treatment if timely primary percutaneous coronary intervention (PCI) is unavailable. Full-dose tenecteplase is associated with an increased risk of intracranial hemorrhage in older patients. Whether pharmaco-invasive treatment with half-dose tenecteplase is effective and safe in older patients with STEMI is unknown.
218. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial.
作者: Justin A Ezekowitz.;Ciaran J McMullan.;Cynthia M Westerhout.;Ileana L Piña.;Jose Lopez-Sendon.;Kevin J Anstrom.;Adrian F Hernandez.;Carolyn S P Lam.;Christopher M O'Connor.;Burkert Pieske.;Piotr Ponikowski.;Lothar Roessig.;Adriaan A Voors.;Joerg Koglin.;Paul W Armstrong.;Javed Butler.; .
来源: Circ Heart Fail. 2023年16卷9期e010599页
We examined whether the primary composite outcome (cardiovascular death or heart failure hospitalization) was related to differences in background use and dosing of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction enrolled in VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction), a randomized trial of vericiguat versus placebo.
219. Final 3-Year Outcomes of a Randomized Trial Comparing a Self-Expanding to a Balloon-Expandable Transcatheter Aortic Valve.
作者: Jonas Lanz.;Helge Möllmann.;Won-Keun Kim.;Christof Burgdorf.;Axel Linke.;Simon Redwood.;Michael Hilker.;Michael Joner.;Holger Thiele.;Lars Conzelmann.;Lenard Conradi.;Sebastian Kerber.;Christian Thilo.;Stefan Toggweiler.;Bernard Prendergast.;Oliver Husser.;Stefan Stortecky.;Sarah Deckarm.;Arnaud Künzi.;Dik Heg.;Thomas Walther.;Stephan Windecker.;Thomas Pilgrim.; .
来源: Circ Cardiovasc Interv. 2023年16卷7期e012873页
In the SCOPE I trial (Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis), transcatheter aortic valve implantation with the self-expanding ACURATE neo (NEO) did not meet noninferiority compared with the balloon-expandable SAPIEN 3 (S3) device regarding a composite end point at 30 days due to higher rates of prosthetic valve regurgitation and acute kidney injury. Data on long-term durability of NEO are scarce. Here, we report whether early differences between NEO and S3 translate into differences in clinical outcomes or bioprosthetic valve failure 3 years after transcatheter aortic valve implantation.
220. Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.
作者: Kamrouz Ghadimi.;Jhaymie L Cappiello.;Mary Cooter Wright.;Jerrold H Levy.;Benjamin S Bryner.;Adam D DeVore.;Jacob N Schroder.;Chetan B Patel.;Sudarshan Rajagopal.;Svati H Shah.;Carmelo A Milano.; .
来源: Circulation. 2023年148卷17期1316-1329页
Right ventricular failure (RVF) is a leading driver of morbidity and death after major cardiac surgery for advanced heart failure, including orthotopic heart transplantation and left ventricular assist device implantation. Inhaled pulmonary-selective vasodilators, such as inhaled epoprostenol (iEPO) and nitric oxide (iNO), are essential therapeutics for the prevention and medical management of postoperative RVF. However, there is limited evidence from clinical trials to guide agent selection despite the significant cost considerations of iNO therapy.
|